{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:08:58Z","timestamp":1792174138934,"version":"4.4.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.pharma.2022.09.001","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T10:46:12Z","timestamp":1663411572000},"page":"267-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Validated stability indicating chromatographic method for determination of baricitinib and its degradation products in their tablet dosage form: Implementation to content uniformity and in vitro dissolution studies"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3946-5465","authenticated-orcid":false,"given":"M.A.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2022.09.001_bib0070","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.drudis.2020.11.025","article-title":"Expanded access programs, compassionate drug use, and emergency use authorizations during the COVID-19 pandemic","volume":"26","author":"Rizk","year":"2021","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharma.2022.09.001_bib0075","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited p1r00ior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.pharma.2022.09.001_bib0080","unstructured":"British Pharmacopoeia Stationary Office, Medicines and Healthcare Products Regulatory Agency. 2022; London, Vol. II."},{"key":"10.1016\/j.pharma.2022.09.001_bib0085","unstructured":"The United States Pharmacopoeia 43 Revision, NF 38. 2022; the United States Pharmacopoeia Convention Inc."},{"key":"10.1016\/j.pharma.2022.09.001_bib0090","first-page":"4","article-title":"Development and validation of a stability indicating related substances of baricitinib by RP-HPLC and its degradation","volume":"4","author":"Mohan","year":"2019","journal-title":"Int J Manag Hum"},{"key":"10.1016\/j.pharma.2022.09.001_bib0095","first-page":"40","article-title":"Development and validation of RP- HPLC Method for baricitinib using quality by design approach and its application to stability studies","volume":"12","author":"Mannurkar","year":"2021","journal-title":"IJPQA"},{"key":"10.1016\/j.pharma.2022.09.001_bib0100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3797\/scipharm.1510-08","article-title":"Simultaneous quantification of baricitinib and methotrexate in rat plasma by LC-MS\/MS: Application to a pharmacokinetic study","volume":"84","author":"Veeraraghavan","year":"2016","journal-title":"Sci Pharm"},{"key":"10.1016\/j.pharma.2022.09.001_bib0105","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/molecules25071600","article-title":"A hydrophilic interaction liquid chromatography-tandem mass spectrometry quantitative method for determination of baricitinib in plasma, and its application in a pharmacokinetic study in rats","volume":"25","author":"Ezzeldin","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.pharma.2022.09.001_bib0110","doi-asserted-by":"crossref","first-page":"488","DOI":"10.22270\/jddt.v9i4-s.3230","article-title":"Development and Validation of UV Spectroscopic Method for Estimation of Baricitinib","volume":"9","author":"Gandhi","year":"2019","journal-title":"J Drug Delivery Ther"},{"key":"10.1016\/j.pharma.2022.09.001_bib0115","doi-asserted-by":"crossref","first-page":"113532","DOI":"10.1016\/j.jpba.2020.113532","article-title":"Determination of acid dissociation constants, enthalpy, entropy and Gibbs free energy of the baricitinib by the UV-metric and pH-metric analysis","volume":"191","author":"Meloun","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2022.09.001_bib0120","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s10337-019-03763-4","article-title":"Development and validation of different chromatographic methods for analysis of cabergoline in the presence of its degradation products: studying degradation profile","volume":"82","author":"Farid","year":"2019","journal-title":"Chromatographia"},{"key":"10.1016\/j.pharma.2022.09.001_bib0125","first-page":"555886","article-title":"Comparative in-vitro dissolution studies for determination of cefixime in an innovator product of suprax powder for oral suspension dosage form using Rp-Hplc method","volume":"14","author":"Hassouna","year":"2018","journal-title":"Glob J Oto"},{"key":"10.1016\/j.pharma.2022.09.001_bib0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","article-title":"Development of forced degradation and stability indicating studies of drugs-A review","volume":"4","author":"Blessy","year":"2014","journal-title":"J Pharm Anal"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:37:27Z","timestamp":1757720247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450922001158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0003450922001158"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2022.09.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validated stability indicating chromatographic method for determination of baricitinib and its degradation products in their tablet dosage form: Implementation to content uniformity and in vitro dissolution studies","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2022.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}